Literature DB >> 12832217

Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis.

Xin Wei1, Chen Liang, Matthias Götte, Mark A Wainberg.   

Abstract

The M184V mutation in HIV reverse transcriptase (RT) is associated with high-level resistance against the nucleoside inhibitor lamivudine as well as diminished viral replication capacity. We have previously demonstrated that HIV variants containing the M184V mutation were relatively unable to successfully undergo compensatory mutagenesis following deletion of an A-rich loop located upstream of the primer binding site (PBS). To understand the mechanisms involved, we synthesized viral RNA templates containing different compensatory mutations that were emergent during the long-term culture of the A-rich loop-deleted viruses. These templates were then used in cell-free reverse transcription initiation assays and in tRNA primer placement assays performed with either recombinant wild-type RT or recombinant RT containing the M184V substitution. The results showed that the RNA template that contained the A-rich loop deletion was impaired in ability to initiate reverse transcription and that the presence of the M184V substitution in RT amplified this effect. Clearance from pausing at position +3 during synthesis of viral DNA was identified as a sensitive step in this reaction that could not be efficiently bypassed with the M184V mutant enzyme. Increased efficiency of initiation was seen with the deleted RNA templates that also contained mutations identified in the revertant viruses, provided that these mutations facilitated formation of a competent binary tRNA/RNA complex. These findings provide biochemical evidence that initiation of tRNA(Lys3)-primed DNA synthesis is an important rate-limiting step in reverse transcription that correlates with viral replication fitness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832217     DOI: 10.1016/s0042-6822(03)00173-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey.

Authors:  Muammer Osman Köksal; Hayati Beka; Nadine Lübke; Jens Verheyen; Haluk Eraksoy; Atahan Cagatay; Rolf Kaiser; Baki Akgül; Ali Agacfidan
Journal:  Med Microbiol Immunol       Date:  2015-04-28       Impact factor: 3.402

Review 3.  HIV-1 replicative fitness in elite controllers.

Authors:  Michael A Lobritz; Kara G Lassen; Eric J Arts
Journal:  Curr Opin HIV AIDS       Date:  2011-05       Impact factor: 4.283

4.  Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.

Authors:  Alonso Heredia; Charles Davis; Mohammed N Amin; Nhut M Le; Mark A Wainberg; Maureen Oliveira; Steven G Deeks; Lai-Xi Wang; Robert R Redfield
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

5.  Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Authors:  Thomas A Toni; Eugene L Asahchop; Daniela Moisi; Michel Ntemgwa; Maureen Oliveira; Bernard Masquelier; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

6.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

7.  Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Authors:  George K Hightower; Scott L Letendre; Mariana Cherner; Sarah A Gibson; Ronald J Ellis; Tanya J Wolfson; Anthony C Gamst; Caroline C Ignacio; Robert K Heaton; Igor Grant; Douglas D Richman; Davey M Smith
Journal:  Virology       Date:  2009-09-16       Impact factor: 3.616

8.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

9.  Biochemical mechanism of HIV-1 resistance to rilpivirine.

Authors:  Kamalendra Singh; Bruno Marchand; Devendra K Rai; Bechan Sharma; Eleftherios Michailidis; Emily M Ryan; Kayla B Matzek; Maxwell D Leslie; Ariel N Hagedorn; Zhe Li; Pieter R Norden; Atsuko Hachiya; Michael A Parniak; Hong-Tao Xu; Mark A Wainberg; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-09-06       Impact factor: 5.157

10.  Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:  Barbara A Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Journal:  Viruses       Date:  2012-08-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.